Search results for "Tumor associated antigen"
showing 6 items of 6 documents
MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.
2018
Abstract To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I immunoprecipitation followed by elution of MHC class I-loaded peptides in breast cancer cells. We determined the sequence of 3196 MHC class I ligands representing 1921 proteins from a panel of 20 breast cancer cell lines. After removing duplicate peptides, i.e., the same peptide eluted from more than one cell line, the total number of unique peptides was 2740. Of the unique peptides eluted, more than 1750 had been previously identified, and of these, sixteen have been shown to be immunogenic. Importantly, half of these immunogenic peptides were shared between different breast cancer…
Urine cytology, tumour markers and bladder cancer
1998
Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2.
2010
Fisiopatologia. — Membrane vesicles, shed from in vitro cultured human breast carcinomas cells, inhibit lymphocytes proliferation.
1994
Membrane vesicles are released by the cells of the two human breast carcinoma cell lines 8701-BC and MCF-7. Vesicles express on their surface HLA Class I molecules and tumor associated antigens and they appear to have a strong, dose dependent, inhibitory effect on thymidine incorporation by periferal lymphocytes. Inhibition is evident on both PhA stimulated or non stimulated lymphocytes. The inhibitory effect is visible after three days of culture. Vesicle addition does not cause cytotoxic effects since inhibited lymphocytes are still capable to exclude Trypan blue. No apoptoptic cells were observed.